IRBs seeking more money for clinicals
This article was originally published in The Gray Sheet
Executive Summary
Institutional review board fees of $1,500-$2,000 are becoming increasingly prevalent in clinical agreements, according to Thoratec VP-Regulatory Affairs Donald Middlebrook. When budgeting for trials, "I used to set aside...for the few centers [that required] the charges. Now it's almost standard," the exec told IIR's Clinical Trial Strategies for Medical Devices & Diagnostics conference Sept. 30 in Washington, D.C...
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.